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ABSTRACT
Toxoplasmosis, caused by the parasite Toxoplasma gondii, is a highly prevalent disease found on
every content. An estimated 20-40% of the United States’ population is infected with the parasite
according to IgG seroprevalence. There are two stages of Toxoplasma that cause disease,
tachyzoites which cause the acute phase and the bradyzoites which cause the chronic phase. The
chronic stage will persist for a life-long infection which can reactivate to tachyzoites if the host
becomes immunocompromised, leading to encephalitis and heart failure. Current drug therapies
clinically approved to treat Toxoplasma can only target tachyzoites and can cause adverse
reactions. Therefore, the development of novel drugs to target bradyzoites is critical.
Histone acetylation is a key post-translational modification involved in active transcription, cell
cycle regulation, and DNA repair. There are three points of inhibition in histone acetylation;
lysine acetyltransferases, lysine deacetylase, and bromodomain proteins. Lysine
acetyltransferases and lysine deacetylases have been well characterized while the role of
bromodomain proteins in gene regulation remain relatively unknown. There are six
bromodomain proteins that are only conserved within the apicomplexan phylum making them
ideal drug target due as they are less likely to cause toxicity in humans. Toxoplasma gondii
bromodomain protein 5 is a hypothetical protein unique to parasites with an unknown function.
I hypothesis that TgBDP5 is involved in the gene regulation of a parasite-specific pathway. To
address this hypothesis three aims were investigated. The first aim was to determine the impact
of TgBDP5 on tachyzoite viability. The second investigated a potential homologue in
Plasmodium falciparum. The third was to identify the role of TgBDP5 in gene regulation under
normal tachyzoite conditions.
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Aim one addressed the impact of TgBDP5 on tachyzoite growth. To accomplish this aim, two
parasite strains were generated. The first was the knockout strain to identify the phenotype
resulting from the absence of bdp5. The second was the complement strain which restored bdp5
and ensured any phenotype observed in the knockout, is solely due to the absence of bdp5. As an
obligate, intracellular parasite the viability of Toxoplasma is measured by its ability to invade
host cells, replicate, and egress to cause infection. This process was measured by a plaque assay,
where parasites were inoculated in human foreskin fibroblasts and grown over 5 days. Total
plaque count and average plaque area were measured confirming that TgBDP5 is non-essential
for tachyzoite viability.
The second aim investigated the complex bdp5 is involved in. A triple HA tag was integrated at
the 3’end of TgBDP5, but a stable line could not be generated. Experimental data from the
Jeffers lab has indicated that TgBDP5 is likely in a complex with TgBDP1. The Plasmodium
falciparum homologue of bdp1 has been extensively studied. Using bioinformatic analysis the
proteins involved in the P. falciparum complex was compared to proteins in Toxoplasma.
TgBDP5 was aligned with a possible homologue that is also found in the PfBDP1 complex.
The third aim investigated genes that are targeted by TgBDP5. To accomplish this a global
transcriptomic analysis was performed on the knockout, complement, and parental strain under
normal tachyzoite growth. This was used to identify genes that are differently expressed in the
absence of TgBDP5.
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CHAPTER I: INTRODUCTION
Overview
The apicomplexan parasite, Toxoplasma gondii, is one of the most prevalent parasites in the
world and can be found on every continent. The prevalence of this disease can range based on
the country, from 10-97.4% (Pinto-Ferreira et al. 2019). Based on IgG seroprevalence it is
estimated that 20-40% of the United States’ population is infected with the parasite (Bigna et al.
2020).
The drug therapies clinically approved for treatment against Toxoplasma have serious side
effects and are unable to treat humans infected with the chronic form (Ben-Harari, Goodwin, and
Casoy 2017). Histone acetylation has been considered a possible drug target as this process is an
essential post translational modification in Toxoplasma that regulates gene expression.
Bromodomain proteins are one of three points of inhibition in histone acetylation and unlike the
other two points they have not been studied extensively. Six of the twelve bromodomain proteins
are only conserved in apicomplexan parasites. This makes them ideal drug targets as it decreases
the risk of toxicity in humans. This paper will investigate the impact of parasite specific
bromodomain protein to gene regulation in Toxoplasma during the acute stage.
Life Cycle of Toxoplasma
The asexual stage of Toxoplasma can infect most animals; however, the parasite only reproduces
sexually in felines (Figure 1-1). Unlike most mammals, cats lack the enzyme involved in the
conversion of linoleic acid to arachidonic acid (Genova et al. 2019). When a feline ingests
infected mice a proteolytic enzyme in their gut will dissolve the cyst wall releasing bradyzoites
1

(Dubey, Lindsay, and Speer 1998). The bradyzoites recognize the linoleic acid in the feline’s gut
and trigger sexual reproduction.
Bradyzoites progress through five stages of schizonts and convert to merozoites which infect
intestinal epithelial cells in the small intestines of cats (English and Striepen 2019). This is
followed by the differentiation into either microgametes or macrogametes. One microgamete
fertilizes the macrogamete, resulting in a zygote which forms the oocyst. Inside each sporulated
oocyst are two sporocysts, from which four sporozoites are developed (Dubey, Lindsay, and
Speer 1998). An infected cat excretes up to a million oocysts in their feces per day, where one
round of mitosis and one round of meiosis occurs resulting in the production of eight haploid
sporozoites. The oocyst has a bi-layered wall that protects it from the environment and chemical
disinfectants, allowing it to remain viable for long periods of time (Salman et al. 2017).
Once the oocyst matures, it becomes highly infectious and can infect intermediate hosts through
ingestion. Asexual reproduction occurs in the non-feline mammals and birds that ingest the
infectious oocysts (Figure 1-1). The sporozoite, inside the sporulated oocysts, will infect the
intestinal epithelium where they differentiate into tachyzoites, causing the acute stage of
infection (Black and Boothroyd 2000). Tachyzoites proliferate rapidly through the host, with a
generation time of six to eight hours. They infect the host cells, replicate, then egress the host
cell. The rate at which tachyzoites invade, replicate, and egress depends on the strain of
Toxoplasma and the type of host cell.
In a healthy host, the immune system places pressure on the tachyzoites to differentiate to
bradyzoites, initiating the chronic stage of the disease. Within 1-2 weeks of infection, tissue cysts
that contain bradyzoites form (Black and Boothroyd 2000). These tissue cysts localize to muscle
tissue, the brain, and other organs, where the cysts persist as a lifelong untreatable infection. The
2

slow replication rate of bradyzoites, does not trigger a host inflammatory response (Dubey,
Lindsay, and Speer 1998). At a slow rate, bradyzoites sporadically differentiate back into
tachyzoites but an intact immune system prevents tachyzoites from disseminating throughout the
host. In an immunocompromised host the tachyzoites will quickly proliferate through the host.
The sustained infection results in tissue damage and without treatment leads to encephalitis,
pneumonitis, or heart failure.

Figure 1 The lifecycle of Toxoplasma gondii. Felines shed oocysts in their feces which can be ingested by
intermediate hosts. When felines eat intermediate hosts infected with the parasite, they will become infected. There
are two typical routes that humans become infected: either by ingesting tissue cysts in undercooked meat or by
ingesting the oocysts. Pregnant women can transmit the parasite to their fetus through vertical transmission. Figure
created with BioRender.com.

Humans typically become infected with Toxoplasma by ingesting tissue cysts in undercooked
meat, ingesting oocysts excreted by felines, or through tachyzoites from a congenital infection
(Vern B. Carruthers and Suzuki 2007). Livestock, such as sheep and pigs can become infected
3

with the oocysts, which result in the formation of tissue cysts. Humans can then become infected
by ingesting undercooked meat. Humans can also encounter the oocysts directly through
contaminated water or when changing the litter box of their feline pets. A woman infected for the
first time while pregnant can pass the infection along to her fetus when tachyzoites cross the
placenta.
Clinical Presentation
An active immune system will target the tachyzoites inducing the differentiation into bradyzoites
causing the host to experience a short acute phase with either mild or no symptoms. In vivo
studies have shown that Toxoplasma is capable of infecting virtually any nucleated cell in the
host, but persist as tissue cysts in the central nervous system while they are often eliminated from
other peripheral organs (Schlüter and Barragan 2019). Neurons and skeletal muscle cells provide
the ideal environment for differentiation; this includes host cell factors like metabolism and
inflammatory response (Lüder and Rahman 2017).
It is unknown what impact the tissue cyst’s localization to the brain has on the host. Mice studies
have shown a reduction in fear response and anxiety in strain dependent manner (Gonzalez et al.
2007; Kannan et al. 2010). Human studies have suggested a correlation between the chronic
infection of Toxoplasma and a decrease in cognitive function (Vern B. Carruthers and Suzuki
2007; Dickerson et al. 2014). These cysts are untreatable and will persist until the host becomes
immunocompromised.
Reactivation of tachyzoites primarily occurs in the central nervous system due to the localization
of tissue cysts. Proliferation of tachyzoites cause host cell death and inflammation. Infection
triggers the production of IFN-y response, which is regulated by anti-inflammatory cytokines
such as IL-10 and IL-27 (Gazzinelli et al. 1996; Stumhofer et al. 2006; Wilson et al. 2005). In a
4

compromised immune system, the inflammatory response is not regulated and there is an
overproduction of IFN-ℽ, leading to inflammation of the brain which can be fatal. Tissue cysts
located in the brain that reactivate will often lead to Toxoplasmic Encephalitis without treatment.
Ocular Toxoplasmosis (infection of the eye) manifests as retinochoroiditis and occurs worldwide
but has the largest burden in developing countries (Maenz et al. 2014). In an immunocompetent
host, the tissue cysts develop with mild or no symptoms depending on the location of the lesion
(Stokkermans and Havens 2020). Toxoplasma retinochoroiditis presents as a small peripheral
lesions and blurry vision without systemic signs (Stokkermans and Havens 2020). Toxoplasma
retinochoroiditis results an inflammatory response in the retina and a granulomatous in the
vascular layer of the eye. Reactivation of the infection could lead to permanent eye damage,
blurred vision, and elevated intraocular pressure (Delair et al. 2011; Westfall et al. 2005).
Diagnosis relies on clinical examination of the necrotizing chorioretinitis that presents as a lesion
with rough margins. Treatment is based on the location of the lesion and if vision is likely to be
affected.
Drug therapies approved for clinical use in humans are active only against tachyzoites, while the
tissue cysts remain impervious to treatment. The most commonly used drugs to treat
toxoplasmosis are pyrimethamine and sulfadiazine (Montazeri et al. 2018). These drugs target
the folate synthesis pathway by inhibiting dihydrofolate reductase and dihydropteroate synthase
respectively (Ben-Harari, Goodwin, and Casoy 2017). However, dihydrofolate reductase is also
present in humans and can cause suppression of bone marrow, requiring the use of folic acid to
counteract the hematologic toxicity (Alday and Doggett 2017). Furthermore, sulfadiazine has
been found to cause serious allergic reactions and toxicity in humans. These drugs can cause
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serious adverse reactions that are potentially fatal. It is critical that new drugs are developed that
are safer for patients and that can treat the chronic stage.
Evolution of Toxoplasma gondii
Toxoplasma belongs to the coccidian subclass of the Apicomplexan phylum. Members of the
coccidian subclass include Toxoplasma, Hammondia, and Neospora. Coccidian parasites share
life cycle features such as the differentiation between tachyzoites and bradyzoites.
Hammondia is an avirulent relative of Toxoplasma sharing genome synteny of >95% (Walzer et
al. 2013). Like Toxoplasma, their definitive hosts are the felines and intermediate hosts include
any warm-blooded animal. Hammondia replicates only a few times before differentiating to
bradyzoites (Dubey and Sreekumar 2003). It is unknown if Hammondia is capable of
reactivation to tachyzoites.
Prior to 1988, Neospora caninum was misidentified as Toxoplasma(Dubey et al. 1988).
Neospora is capable of infecting most warm-blooded animals but is only capable of sexual
reproduction in canines. The parasite causes Neosporosis and is a serious threat to livestock, as it
causes neonatal mortality (Dubey, Schares, and Ortega-Mora 2007). Neospora evades the host
immune response by differentiating to bradyzoites and the reactivation to tachyzoites is
correlated to vertical transmission (Sokol-Borrelli, Coombs, and Boyle 2020).
There is only one species in the genus Toxoplasma; however, the host response and survival can
vary based on the strain of Toxoplasma infecting the host. There is a wide range of genetic
variation between different strains of Toxoplasma. The three major strains are type I, II, and III.
A review conducted by Hosseini and colleagues (2018) examined 26 studies on Toxoplasma
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genetic diversity and found that type II is the most prevalent strain in Europe and North America,
with type I and III found at lower rates (Hosseini et al. 2018).
Type I parasites are highly virulent in the acute phase and less readily differentiate to the chronic
phase (Howe and Sibley 1995). Type II and III parasites can maintain the bradyzoite form which
causes the chronic phase of Toxoplasmosis. Type II parasite strains are less virulent in the acute
phase and produce high cyst burdens (Pavesio et al. 1992).
Lytic Cycle
Toxoplasma is an obligate, intracellular parasite, so it must invade and replicate within a host cell
to survive. The process of invasion, replication, and egress from the host cell is called the lytic
cycle. During the acute infection, the tachyzoites rapidly complete this cycle repeatedly as they
infect the host. Like all apicomplexans, Toxoplasma has an apical complex that is essential for
infection. The apical complex is made up of secretory organelles and cytoskeletal elements. All
apicomplexans have an apical polar ring, which functions as a microtubule-organizing center (N.
S. Morrissette and Sibley 2002). Two microtubules are inside the conoid, which are located
between two rhoptries (Hu, Roos, and Murray 2002). During invasion the conoid will extend out
of the apical polar ring to penetrate the host intestinal epithelium (N. S. Morrissette and Sibley
2002).
Extracellular tachyzoites are motile and will disseminate throughout the host before attaching to
a host cell. Tachyzoites contact the potential host cell at the surface protein coat, made up of
glycosylphosphatidylinositol-linked proteins including surface antigen protein 1. These proteins
mediate the attachment process after surface antigen protein 1 recognizes the sulfated
proteoglycans located on the host cell (He et al. 2002). After the initial recognition, micronemes
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are secreted from the apical end to form a reversible attachment and then discharge adhesive
proteins to enable gliding motility (Soldati and Meissner 2004). This allows the parasite to glide
over the surface of host cell to find a site of entry. The microneme protein AMA1 mediates the
reorientation process of bringing the apical end of the parasite in contact with the host cell
(Mitchell et al. 2004). The RON 2,4,5 complex interacts with AMA1 to form the moving
junction at the point of contact between the parasite and host plasma membrane (Alexander et al.
2005). The moving junction acts as a barrier to prevent host antibodies from entering.
The moving junction mediates the invagination of the host cell plasma membrane in the parasite
vacuole (Mordue et al. 1999; Suss-Toby, Zimmerberg, and Ward 1996). The moving junction
excludes transmembrane proteins from the parasitphorous vacuole (Mordue et al. 1999). The
rhoptry bulb proteins (ROPs) are secreted into the host cell cytoplasm to evade the host immune
system (Beckers et al. 1994).
After invading the host cell, the tachyzoite resides inside the parasitphorous vacuole where it
secretes dense granule (GRA) proteins from the anterior and posterior ends (V. B. Carruthers and
Sibley 1997). The parasitphorous vacuole is modified by GRA proteins with the formation of the
multilamellar vesicles which increased the surface area (Sibley et al. 1995). While most GRA
proteins localize to the parasitphorous vacuole some will traffic to host cytoplasm or nucleus
(Mercier and Cesbron-Delauw 2015). GRA proteins have a wide range of functions but generally
modulate the host cell response to the parasite. For example, GRA16 and GRA24 reach the host
nucleus and alter the host gene expression to regulate the cell-cycle progression or host
inflammatory response respectively (Bougdour et al. 2013; Braun et al. 2013).
There are two distinct stages of Toxoplasma tachyzoites, intracellular and extracellular. There is
a change in gene expression during the transition from extracellular to intracellular environments
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(Gaji et al. 2011). Extracellular parasites upregulate invasion and motility genes and invasion
activates the regulatory mechanisms to increase DNA replication and metabolic genes.
Transcriptional Regulation
Gene expression in Apicomplexan parasites rely on the basal transcription machinery, which is
composed of RNA polymerase II and general transcription factors (Gissot and Kim 2008).
Sequence-specific transcription factors and chromatin remodelers work in combination to
regulate the basal transcription machinery (Gissot and Kim 2008). Apicomplexans have
transcription factors with the Apetala2-intergrase DNA binding domain, which has homologues
in plants (Balaji et al. 2005).
Epigenetic regulation is critical for modulating gene expression in Toxoplasma. This regulation
is partly dependent on posttranslational modifications (PTMS) on histones. Similarly, to other
eukaryotes, the four core histones in Toxoplasma are H2A, H2B, H3, and H4. Toxoplasma and
other apicomplexans do not appear to have retained the histone H1 linker. The histones share a
conserved C-terminus with a histone fold in the globular domain and N-terminal tails (Nardelli et
al. 2013). The C terminal is involved in nucleosome structure and the N-terminal is open to
PTMs (Nebbioso et al. 2012). Histone H3 and H4 are highly conserved with histones in
mammals and other apicomplexans as are the PTMs that have been identified to date (Nardelli et
al. 2013). In addition to the core histones there are variant histones important for transcriptional
activation and silencing (Kamakaka and Biggins 2005). In nucleosomes, chromosomal DNA is
tightly wrapped around histones. The chromatin is tightly condensed DNA, the compact nature
acts as barrier for transcription factors to access the DNA. These histones are targeted by PTMs
that open chromatin to all binding of transcription factors or condense it to prevent binding.
PTMs include acetylation, methylation, and phosphorylation (Iizuka and Smith 2003). PTMs
9

individually regulate the chromatin as well as work in combination. The PTMs generate a
histone code that can be read by the basal transcription machinery. They can have wide range of
Table 1-1 Toxoplasma genes involved in histone
acetylation organized by domains and conservation.

functions depending on which histone residue

Human
Homologue
Lysine Deacetylases
TgHDAC1
+
TgHDAC2
+
TgHDAC3
+
TgHDAC4
+
TgHDAC5
+
TgSIR2
+
TgSIR2-like
+
Lysine Acetracferases
TgGCN5a
+
TgGCN5b
+
TgMYST-A
+
TgMYST-B
+
TgHAT1
+
TgELP3
+
TgATAT
+
Bromodomain
TgGCN5a
+
TgGCN5b
+
TAF1/250
+
TAF2/150
+
TgSET1
+
TgBRG1
+
TgBDP1
TgBDP2
TgBDP3
TgBDP4
TgBDP5
TgBDP6
-

they are modifying, for one it can be an activator

Gene ID

Conserved in
Apicomplexans

and another a repressor of gene expression.
-

Histone Acetylation
Lysine acetylation is a key PTM that is involved
in a wide range of functions like repairing DNA,

-

cell cycle regulation, and active transcription

+
+
+
+
+
+

enzyme lysine acetyltransferases (KATs) add

(Choudhary et al. 2009). This reversable process
is modulated by the “writer” and “eraser”
enzymes and “reader” proteins. The “writer”

acetyl groups, this opens the chromatin allowing
access to complexes with transcription factors.
The “eraser” lysine deacetylases (KDACs)
remove the acetyl group to condense the
chromatin, restricting access from complexes. The

“reader” bromodomain proteins (BRDs) bind and recognize acetylated lysine (Vanagas et al.
2012).
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Lysine Deacetylases
Humans have 18 HDACs that are divided within four classes that are organized by their
sequence similarity to yeast proteins (Seto and Yoshida 2014). Toxoplasma contains five class
I/II homologues of HDAC and two class III SIR2 homologues (Hailu et al. 2017). The HDAC
family has been found to modulate gene repression in pathways such as the homologous
recombination repair and the non-homologous end joining pathways which are critical for DNA
repair (Angel et al. 2020; Miller et al. 2010). Inhibition of TgHDAC3 has been shown to initiate
differentiation of tachyzoite to bradyzoites and disrupted the expression of over 300 stage
specific genes (Bougdour et al. 2009). In Giardia, pharmacological inhibition of HDAC3 blocked
the formation of cysts supporting that epigenetic mechanisms are behind the stage differentiation
process (Sonda et al. 2010). However, another study that investigated the drug on human host
cells found that it targeted at least one mammalian HDAC (Maubon et al. 2010).
TgSIR2 induces the release of cytokines from macrophages that are involved in regulating the
inflammatory response (Yu et al. 2021). Mice vaccinated with recombinant TgSIR2, then
challenged with type I tachyzoites survived significantly longer than naïve mice before
succumbing to infection. The recombinant TgSIR2 increased survival time by an increase of IL10 which is involved in downregulating inflammatory response of the acute phase that causes
tissue damage (Meira et al. 2014; Yu et al. 2021).
Lysine Acetyltransferases
One of the first KATs identified was HAT1 which was found to acetylate histone H4 in yeast
and in humans (Parthun, Widom, and Gottschling 1996; Yang et al. 2011). In yeast, HAT1 has
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been found to be involved in chromatin assembly for DNA repair (Ge, Wang, and Parthun 2011).
A HAT1 homologue is found in humans but it is unknown if it has a conserved function.
The MYST catalytic domain is conserved within eukaryotes and defined by their conserved
acetyl-CoA binding motif, in Toxoplasma both TgMYSTa and TgMYSTb share a C2HC zinc
finger and a chromodomain (Avvakumov and Côté 2007; Smith et al. 2005). Toxoplasma
contains two MYST HATs compared to the five found in humans. The MYST KATs in
Toxoplasma have been found to operate within complexes involved in cellular process; such as
DNA damage response (Vonlaufen et al. 2010).
Higher eukaryotes contain a transcription elongator complex, of which Toxoplasma has a
homologue of Elp3 (TgElp3). TgElp3 is essential to parasite viability and is required to localizes
at the mitochondrion (Stilger and Sullivan 2013). However, due to its unexpected localization in
the outer leaflet of the mitochondrion it is unlikely that TgELP3 is involved in transcription.
Overexpression of TgElp3 is lethal to parasites unless the rSAM domain or transmembrane
domain is impaired (Padgett et al. 2018). The rSAM domains are required for methylation
reactions.
TgATAT is expressed in a cell cycle dependent manner and acetylates α-tubulin lysine 40 during
the daughter parasite formation (Varberg et al. 2016). The acetylation of lysine 40 is essential for
forming inter-protofilament salt bridges that stabilizes microtubules (Cueva et al. 2012).
Essential processes like replication, motility, and invasion rely on microtubules (N. Morrissette
2015). CRISPR/Cas9 disruption of TgATAT resulted in replication defects of incomplete nuclear
division (Varberg et al. 2016).
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The KATs GCN5a and GCN5b KATs contain a bromodomain, which have homologues found in
humans. The GCN5 family proteins have a bromodomain at the C terminal (Bhatti et al. 2006).
GCN5a is non-essential for tachyzoite viability but is essential for the activation of bradyzoitespecific genes in response to stress (Naguleswaran et al. 2010). This differs from GCN5b which
is essential for tachyzoites. GCN5b interacts with AP2-domain proteins and transcription factors
in multiple complexes to contribute to chromatin remodeling and transcription(Wang et al.
2014).
Unlike most invertebrates including other apicomplexans which have one GCN5 HAT,
Toxoplasma has two GCN5 HATs; TgGCN5a and TgGCN5b(Wang et al. 2014). TgGCN5a is
located on chromosome III, while TgGCN5b is found on chromosome LG14 (Bhatti et al. 2006).
They share homology in three of their exons, 3-5 in TgGCN5a and 4-6 in TgGCN5b. The
regions upstream of their HAT domains differ but the actual domain is conserved. Both HATs
contain N-terminal extensions that are not found in other eukaryotes. The N-terminal is essential
for localization of TgGCN5a and TgGCN5b to the nucleus (Bhatti et al. 2006). As expected for
a bromodomain protein, they contain a conserved glutamic acid residue with a carboxyl side
chain to act as a receptor for the six acetylated lysine residues they interact with.
The current drugs approved for clinical use in humans can have severe side effects and cause
toxicity in patients (Ben-Harari, Goodwin, and Casoy 2017). In addition, current treatments only
target the tachyzoite stage. The differentiation between tachyzoites and bradyzoites requires
regulation of stage specific gene expression (Sullivan and Jeffers 2012). PTMs, like lysine
acetylation, have been investigated due to their role as gene regulators. There are the three points
of inhibition in lysine acetylation; KATs, KDACs, and BRDs. KATs and KDACs have been
studied extensively in humans and apicomplexans as potential drug targets with varying degrees
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of success. An issue with drugs targeting one of these proteins is the homology they share with
proteins found in humans which can lead to toxicity.
Bromodomain Proteins in Toxoplasma
Bromodomain proteins were first identified in Drosophila for their role in transcriptional
activation and found to be conserved in humans and yeast (Tamkun et al. 1992). The ~110 amino
acid sequence share a conserved left handed four-helix bundle (Filippakopoulos et al. 2012;
Musselman et al. 2012). Acetylated lysine will contact the hydrophobic cavity formed by the
inter-helical ZA and BC loops, typically it is stabilized by a hydrogen bond with an asparagine
residue of the BC loop(Owen et al. 2000). The binding specificity of the bromodomain is
determined by length and sequence of the BC and ZA loops (Filippakopoulos et al. 2012).
Bromodomain proteins are critical for the regulation of gene expression, and as such are being
investigated for the development of drug therapies targeting apicomplexan parasites. One method
commonly used for inhibiting bromodomains is competitively binding the hydrophobic cavity.
This was used in a Trypanosoma cruzi study, inhibition of bromodomain factor 3 impaired
growth and cellular structure of the asexual stage but overexpression of TcBDF3 restored
growth(Alonso et al. 2016). A study on Plasmodium falciparum investigated the effect of 42
inhibiting compounds against the parasite, and a in silco study indicated that the inhibitors
formed a hydrogen bond with the conserved asparagine (Chua et al. 2018). The compounds were
found to impair growth during the asexual stage of the parasites.
There are 12 bromodomain proteins in Toxoplasma. Six of the bromodomain proteins have
homologues in humans while the other six are only conserved in apicomplexans (Table 1-1). The
six-parasite specific bromodomain proteins make good potential drug targets as there may be less

14

risk of toxicity from binding human homologues. The bromodomain and extra-terminal protein
family in humans have been studied extensively for the development of bromodomain inhibitors.
TgBDP5
Toxoplasma bromodomain protein 5 (TgBDP5) is an apicomplexan specific protein with
orthologues in other coccidian parasites. The parasites with the highest degree of homology in
their bromodomain proteins are also those that undergo a similar differentiation process between
tachyzoites and bradyzoites. A prior CRISPR/Cas9 study examined the degree to which each
gene in Toxoplasma contributed to the tachyzoite fitness (Sidik, Huet, and Lourido
2018).TgBDP5 received a -1.48 fitness score, indicating that it was non-essential for in vitro
cultivation of tachyzoites. It is unknown what the function of TgBDP5 is, but it is highly
conserved in coccidian parasites. I hypothesize that TgBDP5 is involved in the gene regulation of
a parasite-specific pathway.
My goal is to determine the contribution of TgBDP5 to parasite gene regulation in the
Toxoplasma tachyzoites. My research has two aims to address this. The first is to determine
TgBDP5’s impact on tachyzoite viability. The second aim investigates the complex(es)
conserved in apicomplexans, that TgBDP5 is likely involved in. The third aim identifies the
genes targeted by TgBDP5 under normalized tachyzoite conditions.
Research Objectives
Aim 1: A knockout of Toxoplasma gondii bromodomain protein 5 (TgBDP5) and complement
strain was generated to determine if TgBDP5 is essential to the viability of Toxoplasma.
Genomic and RT-PCR were used to confirm correct integration of the constructs. Plaque assays
measured the parasites’ ability to complete the lytic cycle and can identify if there is a defect in
the tachyzoite’s ability to proliferate. A decrease in the number or size of plaques in the
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knockout strain compared to the parental and complement strain would indicate a defect in the
lytic cycle. No defect in tachyzoite proliferation was found in the absence of bdp5.
Aim 2: Bromodomain proteins are known to operate within regulatory complex(es) with
transcription factors (Jeffers et al. 2017). Experimental data from the Jeffers lab has indicated
that TgBDP5 is interacting with TgBDP1, which has a Plasmodium falciparum homologue
PfBDP1 known to operate within a gene regulatory complex. Bioinformatic analysis of the
proteins involved in the PfBDP1 complex(es) lead to identifying a potential homologue of
TgBDP5. Alignments of Pf3D7_1124300 and TgBDP5 suggests two regions with high
similarity. To identify the TgBDP1 and TgBDP5 complex(es), a triple HA tag was integrated at
the 3’ end of the endogenous locus of tgbdp5. Transfected populations showed signal for
integration of the HA tag, but a stable line could not be generated.
Aim 3: Transcriptomic analysis by RNA-Seq was performed to compare the global transcript
levels in the tgbdp5 knockout parasite to the parental and the complemented strains. This
identified the genes that are differently expressed in the absence of TgBDP5 and will identify
genes that are both directly and indirectly subject to TgBDP5 control. This was performed on
parasites during normal tachyzoite growth. The results are pending but genes with a 2-fold
disruption are likely regulated by TgBDP5. Differently expressed genes are likely to be
downregulated if TgBDP5 is an activator.
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CHAPTER II: METHODS
Parasite and host cell cultures
Parasite strains used were RHΔku80, RHΔku80Δbdp5, and RHΔku80Δbdp5C. Toxoplasma is an
obligate intracellular parasite, requiring serial passage in host cells. Host media contained
confluent monolayers of human foreskin fibroblasts (HFF) using Dulbecco Modified Eagle
Medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS). Prior to
parasite inoculation, the host medium was replaced with DMEM supplemented with 1% FBS.
Parasites were grown in DMEM until the host cell monolayer was completely lysed at which
point the parasites were transferred to a new flask with confluent HFFs. Host medium and
medium infected with parasites were incubated at 37℃ with 5% CO2. Stocks of the parasite lines
and host cells were stored in liquid nitrogen, host lines were discarded after 20 passages.
Mycoplasma testing was conducted twice a year to check for contamination of Mycoplasma in
cell lines. The Mycoplasma Detection Kit CAT#13100-01 (SouthernBiotech, Birmingham) was
used, and the manufacturer’s protocol was followed.
Toxoplasma DNA and RNA was harvested from fully lysed T-25 or T-150 flasks and centrifuged
at 1500 rpm. The pellets were resuspended in 1x PBS and centrifuged at 1,000xg at 4℃. The
pellets were stored at -80℃ until DNA or RNA isolation was completed.
RNA Isolation by Phenol: Chloroform
Phenol: Chloroform extraction was performed on intracellular Toxoplasma pellets that were
previously harvested. TRI reagent (MilliporeSigma, St. Louis) was added to pellet, vortexed, and
incubated at room temperature. Chloroform was added, shaken, and incubated at room
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temperature. The sample was centrifuged at full speed at 4℃. The top layer was transferred to a
new microcentrifuge tube with Isopropanol and incubated at room temperature. The TURBO
DNA-free REF# AM1907 (Thermo Fisher Scientific, Waltham) was used remove any DNA
contamination according to manufacturer’s protocol. RNA was stored at -80℃ once isolated
until needed.
Transfection
The Type I RHΔKu80 strain was used to generate the parasite lines RHΔku80Δbdp5,
RHΔku80Δbdp5C, and RHΔbdp5-HA. The parasite line has a disruption in the Ku80 gene to
promote homologous recombination to increase efficiency of plasmid integration. The parasites
were transfected with plasmids to modify the endogenous genome at a single locus.
The plasmids were linearized using a restriction site downstream of the fragment to be inserted.
One hundred micrograms of DNA were digested overnight with the enzyme. DNA purification
was performed by adding an equal volume of Phenol: Chloroform, vertexing, and centrifuging at
16,000xg for 5 minutes. The top layer of DNA was transferred to a new tube and an equal
volume of chloroform was added and centrifuged. This step was repeated then DNA was
precipitated by adding 0.1 volume sodium acetate and 2x volume 100% ethanol. The DNA was
incubated at -80℃ for 30 minutes. The precipitated DNA was pelleted by centrifuge at 16,000xg
for 30 minutes at 4℃. The pellet was than washed with cold 70% ethanol and centrifuged at
16,000g for 10 minutes. The pellet was than air dried in the flow hood, then suspended in 100µl
sterile cytomix. The cytomix was made up of 10mM potassium phosphate Buffer pH 7.6,
120mM potassium chloride, 0.15mM calcium dichloride, 25mM (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid) pH 7.6, 2mM Ethylenediaminetetraacetic acid, and 1M
magnesium chloride. The pH of the cytomix was brought to 7.6 with potassium hydroxide. The
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cytomix was supplemented prior to transfection with 15mg adenosine triphosphate and
glutathione.
Extracellular parasites were prepared for transfection by centrifuge at 400xg for 10 minutes. The
pellet was resuspended in 10ml cytomix and centrifuged. The pellet was resuspended in 300µl of
cytomix, which was added to the 100µl of plasmid DNA and transferred to a 2mm gap
electroporation cuvette. An electroporator was used for transfection, the parasites were pulsed
twice with 1700V, 176 pulse length, and 100 milliseconds between pulses. The electroporated
DNA/parasite mix was added to T-25 flasks of confluent monolayer and incubated at 37℃ with
5% CO2.
Drug Selection
Between 24-48 hours after transfection, drugs were added to parasite lines. After the initial
selection drugs were added at the time of inoculation in future passages. The drug depended on
the selection cassette in the transfected plasmid. Parasites containing the pdfhr cassette were
resistant to pyrimethamine which kills parasites by inhibiting the dihydrofolate reductase.
Parasites that have pdfhr integrated were selected for with 1uM pyrimethamine CAT#194180
(MP Biomedicals, Solon) in 100% ethanol.
Parasites with a gene disruption in the uracil phosphoribosyl transferase (UPRT) locus were
selected for using 5uM 5-Fluoro-2’-deoxyuridine Lot# 119676-122132 (Research Products
International, Mt Prospects) in sterile water. The UPRT is responsible for catalyzing uracil to
UMP in the pyrimidine salvage pathway. This pathway is non-essential for tachyzoite viability
but results the loss of UPRT results in parasites resistant to Fluorodeoxyribose.

19

Parasites transfected with the hypoxanthine phosphoribosyl transferase (HXGPRT) cassette were
resistant to the drugs mycophenolic acid and xanthine. Mycophenolic acid blocks the conversion
of inosine 5'-phosphate to XMP, by inhibiting the inosine-5'-monophosphate dehydrogenase
pathway. The HXGPRT allows parasites to bypass the inhibition of inosine-5'-monophosphate
dehydrogenase pathway and convert xanthine to xanthosine monophosphate(Knoll and
Boothroyd 1998). Parasites with the HXGPRT cassette were treated with 25 ug/mL of
Mycophenolic acid in 100% ethanol and 50ug/mL of Xanthine in 100uM KOH.
Parasite Dilution
After multiple rounds of drug selection, the mixed transfected population is diluted to isolate
individual clones to obtain a clone with correct integration of the desired plasmid. To determine
the parasite concentration, extracellular parasites were counted using a hemocytometer CAT#
3520 (Hausser Science, Horsham). The average number per well was multiplied by 25, then
multiplied by 10,000 to get parasites per ml to obtain the parasite concentration of the flask. To
determine parasite per µl, the concentration was divided by 10x106. One parasite per well, was
obtained by 100 divided by the prior number then multiplied by 2 to account for error. Parasites
were then diluted to 1:1000 in 10ml of 1% FBS media and the calculated amount was transferred
to 20ml of 1%FBS. To obtain one parasite per well, 200µl of the media was transferred to each
well in a 96 well plate containing confluent monolayers of HFFs. The plates were left
undisturbed for 3 days, wells were checked to identify which had only one plaque. After 2 more
days of incubation, wells with one plaque were selected. Clones were transferred to 24 well
plates of HFFs and screened for correct integration using PhireTM Tissue Direct PCR Master Mix
(Thermoscientific, Waltham) following manufacturer’s protocol. Clones with a HA tag
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integrated at the protein were screened with immunofluorescence assay in addition to PCR of
genomic DNA.
Genomic PCR
Q5 High fidelity DNA polymerase (New England BioLabs, Ipswich) was used to amplify
genomic sequences for plasmid construction to be transfected into parasites. The reactions were a
total of fifty microliters including 5x Q5 buffer, 5x Q5 High GC Enhancer, and 10mM dNTP
mix, and 0.5µM of each primer, and around 100ng of DNA template. The PCR product was
placed in a SimpliAmp Thermocycler (Thermo Fisher Scientific, Waltham) and followed New
England Biolabs’ thermocycling conditions. PCR products needed for downstream application
were purified using Monarch PCR & DNA Clean Up (New England BioLabs, Ipswich)
according to manufacturer’s protocol.
GoTaq ® Green Master Mix (Promega, Ipswich) was used to amplify genomic DNA for
screening. To obtain the DNA for amplification, DNeasy Blood & Tissue Kits (Qiagen, Hilden)
was used to extract DNA from fully lysed parasites. Qiagen’s protocol was followed with a
modification to the elution process. Instead of eluting the DNA in 200µl, 100µl was used to
increase the concentration of DNA obtained. One microliter of the DNA was used in the 25µl
PCR reaction. The PCR reaction was set up according to Promega’s protocol and thermocycling
reactions in a SimpliAmp Thermocycler (Thermo Fisher Scientific, Waltham).
PCR products were analyzed by gel electrophoresis using 0.8% agarose gel containing 3µl of
ethidium bromide per 100µl. Gels with DNA that was needed for cloning purposes, had the band
with the corresponding DNA size were extracted using Monarch DNA Gel Extraction Kit
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#T1020L (New England BioLabs, Ipswich). The manufacturer’s protocol was followed to elute
the desired DNA in double-distilled water.
Reverse Transcription- PCR
RT-PCR was used to confirm the absence of the bdp5 mRNA transcript in parasite line RHDBP5
and the restoration of bdp5 transcript in RHBDP5C. Omniscript RT kit(Qiagen, Hilden) was
used according to manufacturer’s protocol. Isolated RNA obtained using the phenol: chloroform
method previously described, was thawed on ice. The RNA was added to the master mix made
according to manufacturer’s protocol. The reverse transcription step’s incubation time was
increased to 3 hours at 37℃. The synthesized cDNA was used in PCRs using GoTaq Green
Master Mix (Promega, Madison) as described above.
Restriction Digests
For a diagnostic digest to check for integration of inserts in plasmids, a total reaction of 20µl was
performed. 1µg of enzyme was digested with 0.5µl of enzyme and the buffer corresponding to
that enzyme’s highest activity. Restriction digest was incubated for 1 hour then run on 0.8%
agarose gel. To linearize a plasmid before transfection, a 100µl reaction was performed. 100ug
of DNA was digested with 1µl of enzyme and 5µl of the buffer corresponding to that enzyme.
Restriction digest was incubated overnight.
Ligation
A standard ratio of 3 insert: 1 vector was used, unless otherwise stated. Around 100ng of the
vector DNA was used in each ligation process. For controls the following reactions were set up:
uncut vector without the ligase and cut vector without the ligase. For restriction digests with
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sticky ends, the reaction was incubated at room temperature for 2 hours then heat inactivated at
65℃ for 10 minutes.
Transformation
NEB® 5-alpha Competent E. coli cells (New England BioLabs, Ipswich) were thawed on ice,
then 10pg- 100ng of DNA is added. The competent cells/DNA solution is mixed gently by
flicking the tube. The solution was incubated on ice for 30 minutes then heat shocked at 42℃ to
form pores in which the supercoiled plasmid DNA can enter the cells, then returned to ice. Super
optimal broth with catabolite repression outgrowth media (New England Biolabs, Ipswich) was
added to the heat-shocked cells and incubated at 37℃. After incubation, the transformed
bacterial culture was plated in a lawn onto a LBA plate and grown overnight at 37C.
Plasmid purification (Miniprep)
Isolated colonies of transformed bacteria were selected from the LBA plates (Figure 2-1).
Colonies were grown in LB+ antibiotic media and grown overnight at 37℃ shaking. The bacteria
were pelleted, and the supernatant was removed. The pellet was resuspended in a buffer (pH 8.0)
containing 50mM tris-chloride, 10mM ethylendiaminetetraccetic acid, and RNase A. The sample
was lysed with a buffer containing 200mM NaOH and 1% SDS. Then neutralized in 3M
potassium acetate (pH 5.5). The sample was spun down and the supernatant was transferred to
isopropanol and incubated at room temperature. After centrifuging the pellet was washed with
ethanol, then centrifuged and dried. Plasmid was resuspended in double deionized water.
Maxiprep
After the transformed bacterial culture was confirmed to have correct integration, it was
inoculated in fresh LBA. A Sigma-Aldrich’s kit GeneEluteTM HP Plasmid Maxiprep Kit was
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used to purify plasmids before linearization and transfection (Figure 2-1). The spin format of the
protocol was used with the following changes. To elute the plasmid DNA double-distilled water

Figure 2 Molecular cloning method for transfecting plasmids into Toxoplasma. Cloning plasmids were heat-shocked
into competent E. coli cells, then grown in super optimal broth media. The bacterial culture was plated on LBA and
grown overnight at 37C. To identify if the plasmid has the correct integration of cloning fragments, a miniprep was
performed on an isolated colony of the LBA plate. The purified plasmid was digested at a restriction site and run on
an agarose gel. Plasmids with the correct size were sent out for sequencing at Genewiz. To purify a plasmid for
transfection, maxiprep was performed on the bacterial culture. The plasmid was linearized and transfected into the
parasite through electroporation. Figure created with BioRender.com.

was added to the column and let sit for 2 minutes, spun, and then repeated. Sodium acetate and
100% ethanol was added to the eluted water. The solution was incubated at -80℃ for 30 minutes
then spun at 30 minutes. The supernatant was discarded, and the pellet was washed with 70%
ethanol. After centrifuging the pellet was airdried then resuspended in 200µl of double-distilled
water.
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Deletion of BDP5 genes
The plasmid pdfhr_bdp5 was generated by inserting the regions upstream and downstream of
BDP5’s start codon around the dfhr in the pDFHR pyrimethamine-resistant cassette. The
fragments were obtained using PCR amplification on RHΔKu80 DNA. The 1335bp upstream
fragment of the tgbdp5 locus was amplified using primers F1 and R2 (Appendix Table 3). The
size of the amplified DNA was checked by gel electrophoresis and the correct size band was
extracted and purified using the Monarch Gel Extraction Kit #T1020L (New England Biolabs,
Ipswich). The purified DNA was inserted into the pDFHR cassette at restriction site ApaI-HF.
The plasmid was purified through a miniprep, and the plasmid with the insert integrated was
selected for using diagnostic restriction digest at the ApaI site. Next, primers F2 and R2 were
used to amplify the 1932bp downstream of the bdp5 start codon (Appendix Table 3). The
downstream fragment of bdp5 was inserted at restriction sites SpeI-HF and NotI-HF downstream
of the tgdhfr cassette. Constructs with the 5’ and 3’ fragments were selected for using diagnostic
restriction digests and sent out for sequencing at Genewiz to ensure correct integration. The
plasmid was linearized using the enzyme NotI-HF, then transfected using electroporation model#
BTX ECM 830 into RHΔku80 strain. Double homologous recombination inserted pdfhr in the
bdp5 locus. Parasites with pdfhr were selected using Pyrimethamine, 24 hours after transfection.
Genomic PCR amplification was used to confirm the integration of pdfhr at the 5’ and 3’ of the
bdp5 locus, as well as the absence of the start codon of bdp5. Intron spanning primers were used
to confirm the absence of bdp5 transcripts with RT-PCR.
Complementation of the BDP5 gene
Knockout strain RHΔku80Δbdp5 was completed by the integration of the bdp5 coding region at
the uracil phosphoribosyltransferase (UPRT) locus through double homologous recombination.
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The NEBuilder® HiFi DNA Assembly Cloning Kit (New England BioLabs, Ipswich) was used
to generate the complement construct by inserting the 5’ and 3’UTR of the UPRT surrounding
the bdp5 coding region into the Puc19 plasmid. Restriction enzymes BamHi-HF and SalI-HF
were used to linearize the puc19 plasmid. The 5’UTR and 3’UTR of the UPRT and the coding
region of bdp5 were obtained through PCR amplification on the RHΔKu80 strain using HiFi
primers. Primers F3 and R3 were used to amplify the bdp5 coding region. Primers F4 and R4
were used to amplify the 5’UTR of the uprt locus, while F6 and R6 amplified the 3’UTR. A
single reaction was set up to assemble the fragments according to NEBuilder HiFI DNA
assembly protocol. The construct with the correct integrations was selected for using restriction
site Bswi-HF then sent out for sequencing at Genewiz. The plasmid was transfected into
RHΔku80Δbdp5 using electroporation. The parasites were negatively selected for with FUDR
after 24 hours, selecting for clones without the uprt gene. Positive drug selection was used to
maintain the integration of pdfhr at the bdp5 locus. Insertion of BDP5 in the UPRT locus was
confirmed by genomic and RT-PCR (Appendix).
Insertion of HA tag
A triple HA tag was inserted at the 3’ endogenous end of the bdp5 locus using a single
recombination event. Primers F6 and R6 amplified 2086bp of bdp5 before the stop codon from
the RHΔKu80 strain (Appendix Table 3). The fragment was inserted into the Plic_pdfhr plasmid
before the triple HA tag at restriction site PacI. The bdp5 fragment and plasmid were ligated and
transformed into competent cells. Plasmids containing the bdp5 region before the triple HA
coding sequence were selected for using restriction digest at the Sal1 site then sent out for
sequencing at Genewiz. The plasmid was linearized at the BcII site and transfected using the
ECM 830 Square Wave Electroporation system (BTX, Holliston) into the RHΔku80 strain. After
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24 hours parasites were selected for using pyrimethamine. Protein expression was confirmed
through anti-HA Immunofluorescence assay (IFA). PCR amplification was done to confirm the
integration of the HA tag.
Type II Knockout Strain
The BDP5 knockout parasites were generated using CRISPR-Cas9 with the Spcas9 plasmid
with sgRNA guide targeting bdp5. Primers F14 and R13 were used for site directed mutagenesis
to replace Spcas9 plasmid’s sgRNA sequence to AAAGCTTCTGAAATCGACGG targeting
BDP5. The restriction enzyme NotI-HF were used to linearize spcas9 plasmid. The plasmid with
the correct sgRNA sequence was selected for using restriction digest and sent out for sequencing
at Genewiz. Primers F15 and R14 with 20bp of bdp5 were used to amplify the HXGPRT drug
cassette (Appendix Table 3). The plasmid containing the sgRNA targeting bdp5 and the DNA
sequence with HXGPRT were co-transfected with into PruΔKu80 parasites. The parasites were
selected with mycophenolic acid and xanthine then diluted through 96 well plates to isolate a
single parasite. PCR amplification was used to confirm gene disruption.
Plaque Assays
Plaque assays were used to measure the parasites’ ability to successfully reproduce in vitro. A
confluent monolayer of HFFs maintained in DMEM were infected with 200 parasites of the
RHΔku80, RHΔku80Δbdp5, and RHΔku80Δbdp5C strains in the intracellular stage. Parasites
were harvested by scraping the infected monolayer and syringe lysed four times. The parasites
were centrifuged at 1500rmp for 10 minutes then resuspended in 1ml Toxoplasma media. The
concentration of the parasite suspension was determined using a hemocytometer. Each parasite
line was diluted to 20mls of Toxoplasma medium, with a concentration of 100 parasites per mL.
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Twelve-well plates containing confluent HFFs were filled with 2mL of Toxoplasma media., this
was done in triplicate for each treatment. The plates grew undistributed for 5 days at 37℃ in 5%
Co2. Plates were then washed with PBS and fixed for 10 minutes with methanol. Crystal violet
was used to stain the host cells to visualize the plaques for 5 minutes then washed with PBS.
Wells were imaged using the Bio-rad chemidoc V3 using trans white light.
Immunofluorescence assay
Confluent HFF monolayers were grown on coverslips in 12-well plates for a week before
inoculation of RHΔku80Δbdp5xHA. Within 24 hours of inoculation, infected monolayers were
fixed with a paraformaldehyde/PBS mixture for 15 minutes then permeabilized in 0.2% Triton
X-100/3% BSA for 15 minutes. The samples were blocked with 3% BSA for one hours and then
incubated with the primary antibody, rat anti-HA(Roche 27573500) Rat 1:2000, in 3% BSA for a
minimum of one hour. The samples were incubated in secondary antibodies, anti-Rat Alexa
Fluor 488 (Thermo A11006) 1:5000, and DAPI in 3% BSA for 1 hour in the dark. Mounted with
mounting reagent on slide. Between each step of the samples were washed three times for 5-10
minutes. The coverslips were mounted to slides using Prolong Diamond Antifade Mountant
CAT#P36965 (Invitrogen, Carlsbad) and viewed under a fluorescence microscopy.
RNA-seq and Analysis
Parasites were inoculated in flasks and grown at 35℃ in 5% CO2 for 36 hours to produce a full
monolayer of approximately 3.7x108 intracellular parasites. The extracellular parasites were
removed from the flask and the monolayer was scraped in cold 1x PBS. The parasites were
syringe lysed and filtered to exclude HFFs from the sample. The parasites were pelleted down
through centrifuge at 4℃. Parasites were kept cold throughout the harvesting process to ensure
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no RNA degradation. The pellet was air dried then treated with Monarch® Total RNA Miniprep
Kit (New England Biolabs, Ispwich). The following modification was made to the protocol,
RNA was eluted into 50µl RNase free water and re-eluted in the water to increase the
concentration. The QubitTM RNA IQ Assay Kit (Invitrogen, Carlsbad) was used according to
manufacturer’s protocol to determine the RNA integrity number, samples with a score over
seven were sent for sequencing.
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CHAPTER III: RESULTS
Conservation of the bromodomain of TgBDP5 in Toxoplasma
The bromodomain sequence of the TgBDP5 was compared with canonical bromodomains.
TgBDP5 contains a conserved bromodomain 88 amino acids long, located in the middle of the
protein (Figure 3-1). The overall conserved structure of a bromodomain is present in TgBDP5 in
comparison to the canonical bromodomains found in humans and Toxoplasma. The canonical
bromodomains maintain the conserved asparagine and tyrosine residues that mediate the binding
of acetylated lysine. In TgBDP5 the conserved tyrosine and asparagine is replaced with a leucine
and cysteine, respectively(Figure 3-1).

Figure 3 The TgBDP5 bromodomains aligned with canonical bromodomains in MUSCLE. Sequences from human
BRD2, human BRD3, human BRD4, human BRDT, Toxoplasma gondii GCN5a and Toxoplasma gondii BDP5.
Green represents identical amino acid residues and blue represents amino acids that are functionally conserved. The
conserved asparagine (N) and tyrosine (Y) that mediate the binding of acetylated lysine are highlighted in red.
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Generation of T. gondii strains RHΔKu80Δbdp5 and RHΔKu80Δbdp5C
To determine the impact of the loss of TgBDP5 on parasite viability and virulence, the selectable
marker dfhr was inserted at the bdp5 locus through homologous recombination, resulting in the
RHΔKu80Δbdp5 parasite line. Knockout construct pDHFR_bdp5 was generated with
homologous bdp5 regions surrounding the dihydrofolate reductase (DHFR) selection marker
(Fig. 3-2A). The construct was linearized with NotI-HF and then transfected into RHΔku80.
Transfectants were treated with pyrimethamine and knockout clones were obtained through
limited dilution in 96 well plates. Pyrimethamine resistant knockout clones were screened for

Figure 4 Generation and complementation of bdp5 knockout strain. A) Cloning strategy for integrating dhfr at the
bdp5 locus to develop the strain Δbdp5. The RHΔKu80 strain was transfected with a plasmid containing
homologous regions of bdp5 locus flanking the selectable marker DHFR. The bottom graphic represents the
resulting edited genome of RHΔKu80Δbdp5. B) Restoration of bdp5 in RHΔKu80Δbdp5 was achieved by
transfecting the strain with a plasmid containing homologous regions of the uprt locus flanking the bdp5 coding
region. The bottom graph represents the resulting edited genome of RHΔKu80Δbdp5C. C) Disruption of bdp5 was
confirmed through the amplification of gPCR1 and gPCR2 using PCR primers F7&R7 and F8&R8 respectively (A).
Complementation was confirmed using PCR primers F10&R10 and F11&R11 to amplify PCR products gPCR4 and
gPCR5 respectively (B). D) Restoration of bdp5 transcripts was confirmed using intron spanning RT-PCR primers
F12&R12 and F13&R11 to amplify PCR products PCR 6 and PCR7 shown in(B).
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integration of dhfr at the bdp5 locus with PCR products PCR1 and PCR2 (Fig. 3-2A,C). Clones
were screened with PCR primers F9&R9 to amplify the bdp5 start codon and upstream region.
Absence of the bdp5 start codon validated the disruption of bdp5 in knockout clones (Fig. 32A,C). RT-PCR products PCR6 and PCR7 showed the disruption of bdp5 transcripts (Fig. 32D).
Complementation of RHΔKu80Δbdp5 was achieved by re-inserting bdp5 at the uracil
phosphoribosyltransferase (UPRT) locus through double homologous recombination. The

Figure 5 Plaque assay performed on parasite lines RHΔku80, RHΔku80Δbdp5, and RHΔku80Δbdp5C. ImageJ was
used to analyze the total plaque number and area. Representative of three biological replicates. Data was normalized
to ΔKu80. A) Two hundred parasites were inoculated into wells with confluent monolayers of human foreskin
fibroblasts. Plaques were visualized by staining with 2% crystal violet 5 days after infection and imaged. Image is
representative of the three biological replicates which performed in triplicates. B) Total number of plaques. C)
Average plaque area.

Puc19-bdp5 was constructed with the 3’ and 5’ UTRs of the uprt flanking the bdp5 coding
region (Figure 3-1B). The plasmid was linearized with KpnI-HF and transfected into
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RHΔKu80Δbdp5. Transfectants were treated with 5-Fluoro-2’-deoxyuridine after twenty-four
hours and resistant parasites were diluted to isolate clones. Clones were screened for the
integration of the bdp5 coding region at the uprt locus was using PCR products PCR4 and PCR5
(Figure 3-2B,C). RT-PCR products PCR6 and PCR7 were amplified to confirm the restoration of
bdp5 transcripts (Figure 3-2C).
Impact of TgBDP5 on Tachyzoite Viability
The impact of TgBDP5 on the viability of tachyzoites was evaluated through the formation of
plaques on confluent HFF monolayers. No difference was seen in plaques by the
RHΔKu80Δbdp5 strain in comparison to RHΔKu80Δbdp5C and RHΔKu80 (Fig 3-3A). Analysis
of total number of plaques and plaque area indicated TgBDP5 is non-essential for tachyzoite
viability (Fig 3-3 B-C).
Table 3-2 Top hits from TgBDP1-3xHA co-immunoprecipitation.
TableGene
3-1 Top
ID hits from TgBDP1-3xHA
Description co-immunoprecipitation.
Localization

TGGT1_264640
TGGT1_264020
TGGT1_278440
TGGT1_202490

TgBDP2
TgBDP5
TgBRG1
AP2VIIa-7

nucleus
nucleus
nucleus
nucleus

BDP5 is A Member of a Complex
Conserved in Apicomplexans
Concurrent research in our lab on

identifying the functional TgBDP1 complex(es) identified interacting proteins through a coimmunoprecipitation. Eleven proteins were pulled down in each replicate, four of which were
bromodomain-containing proteins (Table 3-1). Nine of the eleven proteins localize to the
nucleus. A Plasmodium falciparum homologue of TgBDP1 was identified along with the
apicomplexan conserved complex it belongs to. The P. falciparum complex contains a
homologue of TgBDP2 and Pf3D7_1124300.
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Comparison of Pf3D7_1124300 to TgBDP5
The Plasmodium falciparum protein Pf3D7_1124300 was identified as a potential homologue of
TgBDP5. A multiple sequence alignment by log-expression (MUSCLE) of Pf3D7_1124300 and
TgBDP5 showed they have an overall similarity of 24.5% with 13.9% identical (Figure 3-4).
There are two similar regions between Pf3D7_1124300 and TgBDP5(Figure 3-4a). The region
with the highest similarity is at the C terminal with a 64% similarity and 41% identity in 75
amino acids. An 84 amino acids region in Pf3D7_1124300 has a 43% similarity and 15%
identity to the bromodomain in TgBDP5. Similar to TgBDP5 and its coccidian homologues,
Pf3D7_112430 is missing the conserved tyrosine in the N terminal of the ZA loop and instead
has a leucine (Figure 3-4b). Unlike the coccidian proteins, Pf3D7_1124300 maintains the
conserved asparagine that is required for acetyl-lysine binding(Figure 3-4b).

Figure 6 Alignment of proteins sequences performed in MUSCLE. The first two letters of the accession number
designate the species as follows: Tg, Toxoplasma gondii; Pf, Plasmodium falciparum. A) Comparison of protein
sequences of TgBDP5 and Pf3D7_1124300. The bromodomain in Tgbdp5 is highlighted by the blue the blue box.
The homologous region shared in TgBDP5 and Pf3D7_1124300 is highlighted by the yellow box. B) Comparison of
TgBDP5 to coccidian homologues and Plasmodium protein Pf3D7_112430. Identical amino acid residues are
highlighted in green, blue highlights the functionally similar, and the asterisks mark the location of the conserved
amino acid residues asparagine (N) and tyrosine (Y) .
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Endogenous Tagging of tgbdp5
To identify proteins that interact with TgBDP5, a triple HA tag was integrated at the 3’
endogenous locus of tgbdp5 in the RHΔKu80 strain. The plasmid pBDP5-3xHA_DHFR was
generated with a single homologous region of bdp5 upstream of the HA tag and the dhfr drug
selection marker (Fig. 3-5). The construct was linearized with Bcll-HF and transfected into
RHΔku80 with a single crossover event. Transfectant population was grown overnight and
treated with pyrimethamine. Drug resistant clones were diluted in 96 well plates to isolate clones.
Clones were screened for the integration of the HA tag with immunofluorescence analysis, which
showed a protein with nuclear localization. After passage, the tag was lost from the population.

Figure 7 Integration of the HA tag at the endogenous end of bdp5. Cloning strategy for inserting HA at the 3’
endogenous bdp5 locus. Top: plasmid pLIC_BDP5_3xHA_DHFR. Middle: bdp5 locus. Bottom: Predicted
integration after the single-crossover event at the TgBDP5 locus with integration of the HA tag and DHFR dug
marker.
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Transcriptomic analysis
Transcriptomic analysis was performed by RNA sequencing on the RHΔKu80,
RHΔKu80Δbdp5, and RHΔKu80Δbdp5C. RNA from intracellular parasites were collected and
run on a Qubit assay to confirm an RNA integrity above 7 before sequencing. Results from the
transcriptomic analysis are pending. Genes differently expressed by a 2fold in the
RHΔKu80Δbdp5 strain are likely regulated by TgBDP5. Downregulated genes would indicate
that TgBDP5 is a gene activator. If TgBDP5 is a gene repressor, the differently expressed genes
will be upregulated. Concurrently in Dr. Jeffers lab, RNA-sequencing was performed on
TgBDP1 and sent out for sequencing. A comparison of genes regulated by TgBDP5 and
TgBDP1 will identify genes regulated by the TgBDP1/BDP5 complex(es).
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CHAPTER IV: DISCUSSION
Summary of Results
TgBDP5 maintains the conserved structure of a bromodomain but the two key amino acids
mediating the interaction with acetylated lysine are absent. The absence of asparagine and
tyrosine is also seen in coccidian homologues of TgBDP5. A bdp5 knockout and complement
was generated to determine that TgBDP5 is non-essential for tachyzoite viability. Coimmunoprecipitation of TgBDP1-3xHA suggested an interaction with TgBP5. Investigation of
the TgBDP1 Plasmodium falciparum homologue and the complex it is involved in lead to the
discovery of a potential TgBDP5 homologue. Pf3D7_1124300 was aligned with TgBDP5 to
identify two regions with high similarity. Transcriptomic analysis on TgBDP5 identified genes
both indirectly and directly targeted by TgBDP5, results pending. Genes differently expressed by
both TgBDP5 and TgBD1 are likely regulated by the TgBDP5/TgBDP1 complex(es).
Conservation of the bromodomain of TgBDP5 in Toxoplasma
The sequence of the TgBDP5 bromodomain was compared with several canonical bromodomain.
There are large sequence differences in bromodomain proteins due to the difference in the length
of the ZA and BC loops, but the amino acids required for binding acetyl-lysine are highly
conserved (Jeanmougin et al. 1997). The conserved asparagine, located in helix B, contains a
nitrogen that forms a hydrogen bond with the oxygen of the acetyl carbonyl group to anchor
acetyl-lysine (Figure 3-1) (Owen et al. 2000). Structural analysis suggests that asparagine can be
replaced with other hydrogen bond donors and still bind acetylated lysine residues
(Filippakopoulos et al. 2012). It is unknown if TgBDP5 is a functional bromodomain in the
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absence of this conserved asparagine. Another notable difference in the amino acid sequence is
the leucine located where a tyrosine is typically conserved. The conserved tyrosine in the N
terminal of the ZA loop is found in almost all bromodomains (Figure 3-1), and form watermediated hydrogen bonds to bind the acetyl-lysine (Filippakopoulos et al. 2012). Unlike tyrosine
which has a hydrophilic R group, leucine is hydrophobic as it lacks polarity in its side chain
preventing the interaction with water molecules. TgBDP5 is not the only BRD in Toxoplasma
without the Tyrosine, it is also absent in TgGCN5a, however acetyl-lysine binding has not yet
been demonstrated for this particular protein (Jeffers et al. 2017). There are bromodomain
proteins found in humans that similarly lack the conserved asparagine and tyrosine, such as the
transcriptional corepressor TIF1β which is able to bind acetylated lysine on histones
(Filippakopoulos et al. 2012; Zeng et al. 2008).
TgBDP5 is Non-Essential for Tachyzoite Viability
As an obligate, intracellular parasite, to cause infection Toxoplasma must invade host cells,
replicate, and egress. Growth assays measure the parasites’ ability to complete this cycle and
successfully infect host cells in vitro. Any defect in the parasites’ ability to complete one of the
stages in the lytic cycle would result in a decrease in the number of plaques, or the plaque size in
the knockout strain in comparison to the parental and complement strain.
Through double homologous recombination bdp5 was knocked out in the RHΔKu80 strain to
generate RHΔKu80Δbdp5. The RHΔKu8Δbdp5 strain was viable and displayed no defect in
growth in comparison to the parental strain RHΔKu80 (Figure 3-3A-C). This validates the results
from a previous CRISPR/Cas9 study that examined the degree to which each gene in
Toxoplasma contributed to tachyzoite fitness during in vitro growth (Sidik, Huet, and Lourido
2018). TgBDP5 received a fitness score of -1.48, indicating that it was likely non-essential for
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tachyzoite viability (Sidik, Huet, and Lourido 2018). The fitness score measures the degree to
which a gene contributes to the parasite’s ability to grow in cell culture, on a scale of negative
six to two. Lower scores indicate that the gene is essential for parasite fitness (Sidik et al. 2016).
In addition, genes expressed in other developmental stages were scored as non-essential (Sidik et
al. 2016).
A plaque assay measures tachyzoite growth in vitro but does not reflect the host response to the
infection. Toxoplasma expresses a number of virulence factors that are not required for growth in
vitro but are essential in establishing infection in vitro. Virulence genes like GRA12 and GRA25
have been found to be non-essential in vitro and cause no discernible defects in plaque assays,
however mice challenged with the knockout parasites can survive lethal infection of tachyzoites
(Shastri et al. 2014; Wang et al. 2020, 12). GRA25 increases the release of cytokines by infected
macrophages and GRA12 promotes immune evasion. Virulence genes are essential in
manipulating the host immune response and when absent the parasite is more susceptible to the
host immune defense. It is possible that TgBDP5 could be involved in regulating the expression
of virulence genes. My transcriptomic analysis of tgbdp5 knockout parasites will reveal the
genes subject to TgBDP5 regulation and may identify virulence factors that contribute to in vivo
infection.
Another limitation of the growth assay is that it only measures the parasite’s growth in the
tachyzoite stage. It does not indicate the impact of the absence of the protein in the other stages
including bradyzoites and sexual stages. Proteins that are essential in bradyzoites may show no
defect in tachyzoite growth. An example is LDH1, it is not required for tachyzoite growth in
vitro but is essential for bradyzoite maintenance and cannot maintain cysts without the gene
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(Abdelbaset et al. 2017). This limitation could be addressed by investigating the impact of
TgBDP5 after the addition of alkaline pH to initiate the differentiation to bradyzoites.
Transcriptomic analysis available on ToxoDB is inconsistent but supports that TgBDP5 is
expressed in all stages without any distinct profile in any of the stages (Pittman, Aliota, and
Knoll 2014; Ramakrishnan et al. 2019). This suggests that TgBDP5 may not have a stage
specific function.
BDP5 is A Member of a Complex Conserved in Apicomplexans
Concurrent research being performed in Dr. Jeffers’ lab on bromodomain protein TgBDP1 has
identified an interaction with TgBDP5. A co-immunoprecipitation was performed on HA tagged
TgBDP1, and TgBDP5 was one of the 11 proteins pulled down in each replicate, suggesting
consistent association between TgBDP1 and TgBDP5. Other proteins included TgBDP2 and
TgBRG1, both of which have conserved bromodomains. TgBDP1 has a homologue in
Plasmodium falciparum, whose functional complex has been identified. The P. falciparum
homologue PfBDP1 is in a complex with TgBDP2 homologue PfBDP2 and Pf3D7_1124300.
Pf3D7_1124300 is conserved protein with an unknown function in P. falciparum without an
annotated bromodomain. A study using transposon mutagenesis in P. falciparum gave
Pf3D7_1124300 a fitness score of -2.63, indicating that it is essential for in vitro asexual growth.
Pf3D7_1124300 was found to have two regions with high similarity to TgBDP5, one of which
was within the conserved bromodomain of TgBDP5, and the other at the C terminal region
(Figure 3-4a). Alignment with TgBDP5 and two coccidian homologues suggest Pf3D7_112430
has a BRD-like domain though it is unknown if any are functional. All four proteins have
replaced the tyrosine in the N terminal of the ZA loop with a leucine. Unlike the coccidian
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BRDs, Pf3D7_112430 contains an asparagine suggesting it may be capable of mediating an
acetyl lysine interaction.
Functional TgBDP5 complex
Bromodomain proteins are known to operate within regulatory complexes with transcription
factors(Jeffers et al. 2017). The co-immunoprecipitation(co-IP) of TgBDP1 pulled down
TgBDP5 along with 35 other proteins. It is likely that this is representative of multiple regulatory
complexes that TgBDP1 is involved in. To identify the functional complex(es) of TgBDP5 and
TgBDP1 a co-IP will need to be performed on TgBDP5. A plasmid has been generated to insert a
triple HA tag at the C terminal of TgBDP5 to detect and purify the protein. The proteins pulled
down from the TgBDP5 co-IP will be compared to the TgBDP1 pulldown to identify the shared
proteins. This will identify proteins that are likely in the functional TgBDP5/TgBDP1
complex(es).
Transcriptomic Analysis
The results of the transcriptomic analysis comparing gene expression in the knockout strain to
the parental and complement strains are still pending. Bromodomain proteins often act as gene
activators, if this the case for TgBDP5 then differently expressed will be downregulated in the
knockout (Josling et al. 2012). The P. falciparum homologue is in a gene activator complex with
BDP1, suggesting that the TgBDP5 complex is also an activator. If TgBDP5 is a repressor like
BRD4 in humans, then genes will be upregulated (Sakamaki et al. 2017). If TgBDP5 is
regulating virulence genes, then immune modulators and virulence factors will be
downregulated.
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Future Directions
Site directed mutagenesis a sgRNA guide for bdp5 was inserted upstream of the sgRNA scaffold into a
spCAS9 plasmid. This construct can be transfected into a type II parasite strain. If transcriptomic

analysis shows that TgBDP5 is regulating the expression of virulence genes, then further
experiments should investigate the impact of TgBDP5 in vivo. Mice would be challenged with
type I and II parasite strains to show the impact of TgBDP5 on the host response to infection. A
difference in the parasite strains would show if TgBDP5 has a strain dependent effect. This experiment
would also expand upon TgBDP5 response to immune pressure.
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APPENDIX
Table 3 PCR Primers used for generation, integration, and confirmation of cloning plasmids.

Name Sense/Antisense
F1
Sense
R2
Antisense
F2
Sense
R2
Antisense
F3
Sense
R3
Antisense
F4
Sense
R4
Antisense
F5
Sense
R5
Antisense
F6
Sense
R6
Antisense
F7
Sense
R7
Antisense
F8
Sense
R8
Antisense
F9
Sense
R9
Antisense
F10
Sense
R10
Antisense
F11
Sense
R11
Antisense
F12
Sense
R12
Antisense
F13
Sense
F14
Sense
R13
Antisense
F15
Sense
R14

Antisense

Sequence 5’-3’
TGACACGCTCTGCAACGTGGGTTGATGAACTCG
CCGGTGACTTCATCGTTGCGGGCCCCCCCTC
CGATCCACTAGTGAACGAGTACACTTGCACG
CCTTCTATGCATTCCCACTCGCGGCCGCATACTC
tccttgtcgatcATGGAGCAACCAATCCCTTTG
aagacagcagggcTCAGTAGTCGTCGTCGCTG
tacgccaagcttgcatgcctgcaggGTGAGCTCATGCTGGAGC
ttggttgctccatGATCGACAAGGAGCTTTCC
gacgactactgaGCCCTGCTGTCTTGTCAG
agtgaattcgagctcggtacccgggCGATCGACCGAAGCAACAC
tacttccaatccaatttaattaaGGCGTAAAGCACGAGTGAG
cctccacttccaattttaattaaGTAGTCGTCGTCGCTGCC
GCATGCACATCATACTCAG
CGGTTACCATTCATTCTGC
GGATGACTCTTCATGTGG
gttaactctcgagaggcc
ATGGAGCAACCAATCCC
CGTTCTGCTTGATAGTCG
cctccacaaggcgtattcc
GGAAATGGTTGCCTGGTGC
CCTTCCTCACGCTCCAAAC
CGTGAAGAACACTTCTTGGGC
GCTGGGTAATGTCTACCGC
GCACCAGGCAACCATTTCC
CATCCGACGAGCTTGAACTCG
aaatcgacggCATCAGTTCTGTCAGATTTTC
cagaagctttAAATATGATTCTTGTCAGATGTTG
AGTTCATCGCAGAGTGGGCGAAGAAAGCTTCTGAAATCGACAC
TATAGGGAGAGCGGC
CGGCAGCAATCGGCTGGAGACGCCACTGCGGCCGAGAGGCCAT
CGATTTTCCATGGCAG
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Figure 8 Plaque assays performed in triplicate.

Figure 8 Plaque assays performed in
triplicate.
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Figure 9 Reverse transcriptase PCR confirming knockout and complementation of TgBDP5.

Figure 10 Genomic PCR confirming knockout of TgBDP5.

Figure 12 Genomic PCR confirming
integration of bdp5 at the 5'UTR of the
uprt locus.

Figure 11 Genomic PCR confirming
the integration of bdp5 at the 3'UTR of
the uprt locus.
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Figure 13 pUPRT_bdp5 construct in snapgene.

Figure 14 pLIC-TgBDP5-3xHA-DHFR construct in snapgene.
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Figure 15 pDHFR-TgBDP5 construct in snapgene.
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